Search Results

Nascent Biotech, Inc. announces that it is embarking on a fresh manufacturing run to ensure Pritumumab supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial.

Nascent Biotech, Inc. and HypoSpray Pharma announced today a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab.

Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”), announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent’s lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.

Nascent Biotech, Inc. is pleased to announce that the Company has completed payment of all outstanding variable convertible debt obligations.

Nascent Biotech, Inc. is pleased to announce the Company has been issued a patent from the Japanese Patent Office for its primary asset, Pritumumab.